An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Trial details
- Registry ID
- NCT07220603
- Drugs studied
- PGN-EDODM1
TrialRedline tracks 3 clinical trials sponsored by PepGen Inc: 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)NCT07220603 | PGN-EDODM1 | Recruiting | 2029-01Estimated |
| A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1NCT06667453 | PGN-EDODM1 | Recruiting | 2027-03Estimated |
| A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping TreatmentNCT06079736 | PGN-EDO51 | Terminated | 2025-08-28Actual |
Names as written in the registry records.
NCT06667453 · PepGen Inc
Before: Aug 2026. After: Mar 2027.
Before: Oct 2029. After: Jan 2029.
Before: Not yet recruiting. After: Recruiting.